30th Nov 2021 07:30
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (AS IT FORMS PART OF DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Response to disciplinary notice
Oxford, U.K., 30 November 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the clinical AI company, has agreed settlement terms with the London Stock Exchange for a public censure and fine of £580,000, discounted to £406,000 for early settlement, for historical breaches of AIM Rules 13 and 31 in relation to the payment of certain IPO bonuses in 2018.
Sensyne Health has fully cooperated with the London Stock Exchange during the period of its investigation over the past two years, and both acknowledges and reiterates its apology for its failure to properly understand and meet its AIM disclosure obligations during the first year of its listing as a public company, between November 2018 and October 2019.
Since that period, Sensyne has taken significant steps to strengthen its governance to meet the standards required of a publicly listed company and is committed to upholding these standards. Over the past two years, the Board has overseen the successful implementation of recommendations from a Board effectiveness review conducted by A&O Consulting and recruited four new Independent Non-Executive Directors to strengthen the public market expertise of the Board.
In parallel, the Company has reviewed its corporate governance structure and enhanced its procedures, resources and controls.
The Board would like to thank Peel Hunt LLP, which continues to act as nominated adviser to the Company since admission to AIM in August 2018, for its guidance, advice and steadfast support.
The Exchange Notice is available at: https://www.londonstockexchange.com/resources/raise-finance-resources?tab=aim
-ENDS-
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Dr Richard Pye, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Jessica Hodgson | |
About Sensyne Health www.sensynehealth.com
Sensyne Health plc Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymised data sets to help life sciences companies accelerate the discovery and development of new medicines.
Related Shares:
SENS.L